Alessandro Castellarin, MD
Retina Specialist · Santa Barbara, CANPI 1689773244
Payments from drug & device makers
Across 571 payments — averaging $2001.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$502K
- Ocular Therapeutix, Inc.$357K
- Boehringer Ingelheim International GmbH$174K
- Eyepoint US, Inc.$86K
- Genentech USA, Inc.$5K
- Alcon Research LLC$4K
- plus $15K from 23 others
Across 1 payment — averaging $9600.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ocular Therapeutix, Inc.$10K
What the payments were for
- Consulting fees$10,10742%
- Speaking & faculty fees$6583%
- Travel & lodging$8213%
- Food & beverage$9,89541%
- Gifts$2,1299%
- Ownership interest$2551%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 59 | $502,272 |
| Ocular Therapeutix, Inc. | 65 | $356,565 |
| Boehringer Ingelheim International GmbH | 210 | $173,909 |
| Eyepoint US, Inc. | 5 | $85,828 |
| Genentech USA, Inc. | 36 | $5,464 |
| Alcon Research LLC | 4 | $4,200 |
| Astellas Pharma US Inc | 18 | $3,046 |
| Carl Zeiss Meditec, Inc. | 1 | $2,129 |
| Regeneron Healthcare Solutions, Inc. | 51 | $2,061 |
| AbbVie(2 entities) | 45 | $1,831 |
| Regeneron | 7 | $745 |
| Notal Vision, Inc. | 1 | $658 |
| Alcon | 4 | $528 |
| Novartis | 7 | $496 |
| Apellis Pharmaceuticals, Inc. | 15 | $486 |
| Harrow Eye, LLC | 7 | $348 |
| Sun Pharmaceutical Industries Inc. | 5 | $260 |
| Glaukos Corporation | 2 | $257 |
| US Retina LLC | 2 | $255 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $249 |
| Sight Sciences, Inc. | 2 | $247 |
| Bausch & Lomb Americas Inc. | 3 | $234 |
| Alimera Sciences, Inc. | 10 | $206 |
| Amgen | 2 | $137 |
| Coherus Oncology, Inc. | 2 | $137 |
| Biogen | 1 | $130 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $123 |
| Aerie Pharmaceuticals, Inc. | 1 | $102 |
| ANI Pharmaceuticals, Inc. | 3 | $61 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NGENUITY$4,348
- VABYSMO$4,346
- Izervay$2,595
- VISULAS 532s$2,129
- EYLEA$954
- EYLEA HD$729
- Constellation$380
- Tecnis IOL$370
- IHEEZO$269
- LOTEMAX SM$236
- YUTIQ$163
- iStent inject Trabecular Micro-Bypass Stent System$132
- Lucentis$125
- Cimerli$125
- CE-marked KXLA system$125
- VYZULTA$125
- OMNI(R) SURGICAL SYSTEM (US)$125
- Tecnis Simplicity$123
- OMNI$123
- TEPEZZA$110
How this compares
$1,142,966 in reported general payments places this provider in the 90th percentile of 187 retina specialist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EyleaAflibercept | 28 | $82,258 |
| LumiganBimatoprost | 23 | $9,811 |
| CombiganBrimonidine Tartrate/Timolol | 32 | $8,304 |
| RestasisCyclosporine | 11 | $6,478 |
| Brimonidine Tartrate | 80 | $6,108 |
| Prednisolone Acetate | 125 | $5,900 |
| Bromfenac Sodium | 21 | $5,273 |
| Loteprednol Etabonate | 13 | $3,931 |
| Difluprednate | 42 | $3,799 |
| Atropine Sulfate | 65 | $2,552 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 18 | $1,615 |
| Ketorolac Tromethamine | 70 | $1,139 |
| ErythromycinErythromycin Base | 111 | $1,115 |
| MoxifloxacinMoxifloxacin Hcl | 50 | $1,074 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 77 | $993 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Regeneron Healthcare Solutions, Inc.Eylea | $2,061 | $82,25828 claims |
| AbbVieLumigan, Combigan, Restasis | $1,831 | $24,59266 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $249 | $3,93113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 187 retina specialist providers in California.
Other retina specialist in Santa Barbara
- Dante PieramiciSanta Barbara$15.1M
- Dilsher DhootSanta Barbara$8.2M
- Nathan SteinleSanta Barbara$2.6M
- Nika BagheriSanta Barbara$528K
- Stephen CouvillionSanta Barbara$361K
- Robert AverySanta Barbara$190K
- Daniel LearnedSanta Barbara$146K
- Margaret ChangSacramento$13.2M
- Hani Salehi-HadHuntington Beach$12.2M
- Payam AminiPasadena$9.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.